Fig. 8

Decreased neuroinflammation in the nimodipine-treated cerebellum. A, C, E Representative sagittal sections of brains immunostained for PLP, GFAP, and Iba1. Tissue was collected from untreated subjects and EAE mice treated with vehicle or nimodipine during the acute or peak phase of the disease. Scale bar, 180 μm. B, D, F PLP, GFAP, and Iba1 expression was quantified by analyzing the integrated fluorescence intensity in the corpus callosum (CC) and cerebellum (CB). One-way ANOVA followed by the Bonferroni’s test was used for comparisons between experimental groups. Analysis consisted of at least four brains per condition and each dot denotes the mean of one subject. Values are presented as mean ± SEM ^^p < 0.01, ^^^p < 0.001 versus untreated; **p < 0.01, ***p < 0.001 versus vehicle